Wells Fargo & Company MN Sells 9,987 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Wells Fargo & Company MN decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 32.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,619 shares of the specialty pharmaceutical company’s stock after selling 9,987 shares during the period. Wells Fargo & Company MN owned about 0.06% of Collegium Pharmaceutical worth $591,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. New Age Alpha Advisors LLC bought a new stake in Collegium Pharmaceutical in the 4th quarter worth $40,000. KBC Group NV grew its stake in shares of Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 642 shares during the period. Finally, Aigen Investment Management LP bought a new position in Collegium Pharmaceutical during the 4th quarter valued at approximately $230,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on COLL shares. Needham & Company LLC reissued a “buy” rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 19th. Piper Sandler dropped their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the business’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now directly owns 165,246 shares of the company’s stock, valued at approximately $4,959,032.46. The trade was a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,693 shares of company stock valued at $2,334,994. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Price Performance

COLL opened at $27.65 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a market cap of $888.45 million, a price-to-earnings ratio of 11.92 and a beta of 0.76. The stock has a fifty day simple moving average of $28.19 and a two-hundred day simple moving average of $30.43. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.